Eric Mou, MD
Clinical Assistant Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation
Current Positions
- Clinical Assistant Professor of Internal Medicine-Hematology, Oncology, and Blood & Marrow Transplantation
Education
- MD, University of Iowa Carver College of Medicine, Iowa City, Iowa
- Resident, Internal Medicine, Stanford University, Stanford, California
- Fellow, Hematoloy/Oncology, Stanford University, Stanford, California
- B.S.E., Biomedical Engineering, with highest distinction, University of Iowa, Iowa City, IA
Research Interests
- Exploring treatment patterns, prognostic factors, and outcomes in patients diagnosed with Hodgkin and non-Hodgkin lymphomas
- Investigating novel therapeutics and tailoring treatment for patients with cutaneous T-cell lymphomas
- Conducting clinical research with novel therapeutics and/or treatment paradigms in patients with all subtypes of lymphoma
Licenses & Certifications
- Hematology, American Board of Internal Medicine
- Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Iowa Board of Medicine
Selected Publications
- A Ravindra, E Mou (2025). Incorporating novel therapies into the treatment of older patients with classic Hodgkin lymphoma. Expert Review of Hematology, Jul 13:1-17.
- E Mou, S Fernandez-Pol, S Li, KE Rieger, R Novoa, CJ Suarez, R Wieland, WK Weng, YH Kim, MS Khodadoust (2024). Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas, American Journal of Hematology May:99(5):985-988.
- AM Rodday, SK Parsons, JN Upshaw, JW Friedberg, A Gallamini, E Hawkes, D Hodgson, P Johnson, BK Link, E Mou, KJ Savage, PL Zinzani, M Maurer, AM Evens. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium (2023). Journal of Clinical Oncology, Apr 10;41(11):2076-2086.
- MS Khodadoust, E Mou, YH Kim (2023). Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome, Blood Feb 16;141(7):695-703.
- E Mou, R Advani, R von Eyben, SA Rosenberg, RT Hoppe. Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies), nternational Journal of Radiation Oncology*Biology*Physics Jun 1; 110(2): 444-451.
- E Mou, L Falchi, V Sundaram, JS Abramson, R Balassanian, S Beygi, MJ Fitzpatrick, AK Frank,S Gupta, O Lin, SR Long, JR Menke, DR Reed, R Ruiz-Cordero, AK Volaric, Y Xie, L Wang, KW Wen, SL Zadeh, Y Natkunam, MC Cheung, D Gratzinger. (2021) Impact of Initial Biopsy Type on the Time to Final Diagnostic Biopsy in Patients with Follicular Lymphoma and Suspected Histologic Transformation, Leukemia and Lymphoma, Jun 26; 1-9.
- PB Allen, H Savas, A Evens, R Advani, B Palmer, B Pro, R Karmali, E Mou, J Bearden, G Dillehay, RA Bayer, RM Eisner, JS Chmiel, K O’Shea, LI Gordon, JN Winter. (2021) Pembrolizumab Followed by AVD in Untreated Early Unfavorable and Advanced-stage Classical Hodgkin lymphoma, Blood Mar; 137(10): 1318-1326.
- M Spinner, E Mou, R Advani, (2021). Chapter 96: Hodgkin Lymphoma, In: Kaushansky, Lichtman, Prchal eds. Williams Hematology. 10th ed. McGraw-Hill.
- E Mou, L Schapira, P Kunz. (2018) The Power of Trust, JAMA Oncology Sept; 4(9): 1173-1174
- Mou E, Lazzareschi D, Blayney, D, Connolly A, Rogers AJ. Embolic temblor: a case of rapidly progressive RV failure in a patient (poster). American Thoracic Society International Conference, San Francisco, CA, May 2016. Am J Respir Crit Care Med 2016;193:A2262.